{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:44:00Z","timestamp":1785523440592,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CSL Italy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05298-8","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:13:58Z","timestamp":1785172438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of hyperkalaemia in the Italian clinical practice: impact of diverse potassium binders on outcomes and costs in patients with chronic kidney disease and heart failure"],"prefix":"10.1007","author":[{"given":"Alessandro","family":"Fucili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cappuccilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Leogrande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Soro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cogliati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca Degli","family":"Esposti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"5298_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100879","volume":"6","author":"S Van Boemmel-Wegmann","year":"2024","unstructured":"Van Boemmel-Wegmann S, Bauer C, Schuchhardt J et al (2024) Hyperkalemia incidence in patients with non-dialysis chronic kidney disease: a large retrospective cohort study from United States clinical care. Kidney Medicine 6:100879. https:\/\/doi.org\/10.1016\/j.xkme.2024.100879","journal-title":"Kidney Medicine"},{"key":"5298_CR2","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1093\/ndt\/gfx312","volume":"33","author":"RW Thomsen","year":"2018","unstructured":"Thomsen RW, Nicolaisen SK, Hasvold P et al (2018) Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes\u2014a Danish population-based cohort study. Nephrol Dial Transpl 33:1610\u20131620. https:\/\/doi.org\/10.1093\/ndt\/gfx312","journal-title":"Nephrol Dial Transpl"},{"key":"5298_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/jch.14633","volume":"25","author":"A AlSahow","year":"2023","unstructured":"AlSahow A, AbdulShafy M, Al-Ghamdi S et al (2023) Prevalence and management of hyperkalemia in chronic kidney disease and heart failure patients in the Gulf Cooperation Council (GCC). J Clin Hypertens 25:251\u2013258. https:\/\/doi.org\/10.1111\/jch.14633","journal-title":"J Clin Hypertens"},{"key":"5298_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","volume":"145","author":"IE Beldhuis","year":"2022","unstructured":"Beldhuis IE, Lam CSP, Testani JM et al (2022) Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation 145:693\u2013712. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.052792","journal-title":"Circulation"},{"key":"5298_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40256-023-00605-5","volume":"23","author":"LA Alcocer","year":"2023","unstructured":"Alcocer LA, Bryce A, De Padua Brasil D et al (2023) The pivotal role of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in hypertension management and cardiovascular and renal protection: a critical appraisal and comparison of international guidelines. Am J Cardiovasc Drugs 23:663\u2013682. https:\/\/doi.org\/10.1007\/s40256-023-00605-5","journal-title":"Am J Cardiovasc Drugs"},{"key":"5298_CR6","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/ejhf.1793","volume":"22","author":"P Rossignol","year":"2020","unstructured":"Rossignol P, Lainscak M, Crespo\u2010Leiro MG et al (2020) Unravelling the interplay between hyperkalaemia, renin\u2013angiotensin\u2013aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC\u2010HFA\u2010EORP heart failure long\u2010term registry. Eur J Heart Fail 22:1378\u20131389. https:\/\/doi.org\/10.1002\/ejhf.1793","journal-title":"Eur J Heart Fail"},{"key":"5298_CR7","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/ejhf.2024","volume":"22","author":"M Volterrani","year":"2020","unstructured":"Volterrani M, Perrone V, Sangiorgi D et al (2020) Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study. Eur J Heart Fail 22:2049\u20132055. https:\/\/doi.org\/10.1002\/ejhf.2024","journal-title":"Eur J Heart Fail"},{"key":"5298_CR8","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ et al (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105:S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"5298_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s11897-017-0341-0","volume":"14","author":"EM DeFilippis","year":"2017","unstructured":"DeFilippis EM, Desai AS (2017) Treatment of hyperkalemia in heart failure. Curr Heart Fail Rep 14:266\u2013274. https:\/\/doi.org\/10.1007\/s11897-017-0341-0","journal-title":"Curr Heart Fail Rep"},{"key":"5298_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/nep.70117","volume":"30","author":"T Nakayama","year":"2025","unstructured":"Nakayama T, Kaneko H, Suzuki Y et al (2025) Sodium polystyrene sulfonate and heart failure risk: a comparative study with calcium polystyrene sulfonate. Nephrology (Carlton) 30:e70117. https:\/\/doi.org\/10.1111\/nep.70117","journal-title":"Nephrology (Carlton)"},{"key":"5298_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000543385","volume":"15","author":"N Kreitzer","year":"2025","unstructured":"Kreitzer N, Albert NM, Amin AN et al (2025) EMCREG-International multidisciplinary consensus panel on management of hyperkalemia in chronic kidney disease and heart failure. Cardiorenal Med 15:133\u2013152. https:\/\/doi.org\/10.1159\/000543385","journal-title":"Cardiorenal Med"},{"key":"5298_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10741-024-10461-3","volume":"30","author":"C Fonseca","year":"2024","unstructured":"Fonseca C, Garagarza C, Silva G et al (2024) Hyperkalemia management: a multidisciplinary expert panel\u2019s perspective on the role of new potassium binders. Heart Fail Rev 30:271\u2013286. https:\/\/doi.org\/10.1007\/s10741-024-10461-3","journal-title":"Heart Fail Rev"},{"key":"5298_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1253\/circj.CJ-24-0844","volume":"89","author":"T Kitai","year":"2025","unstructured":"Kitai T, Maruyama S, Kuwahara K et al (2025) Establishing cross-specialty expert consensus on the optimal management of hyperkalemia in patients with heart failure and chronic kidney disease. Circ J 89:470\u2013478. https:\/\/doi.org\/10.1253\/circj.CJ-24-0844","journal-title":"Circ J"},{"key":"5298_CR14","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/ejhf.300","volume":"17","author":"SD Anker","year":"2015","unstructured":"Anker SD, Kosiborod M, Zannad F et al (2015) Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 17:1050\u20131056. https:\/\/doi.org\/10.1002\/ejhf.300","journal-title":"Eur J Heart Fail"},{"key":"5298_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"DK Packham","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT et al (2015) Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 372:222\u2013231. https:\/\/doi.org\/10.1056\/NEJMoa1411487","journal-title":"N Engl J Med"},{"key":"5298_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ehf2.12561","volume":"7","author":"F Zannad","year":"2020","unstructured":"Zannad F, Hsu B-G, Maeda Y et al (2020) Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study. ESC Heart Fail 7:54\u201364. https:\/\/doi.org\/10.1002\/ehf2.12561","journal-title":"ESC Heart Fail"},{"key":"5298_CR17","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1681\/ASN.2019050450","volume":"30","author":"S Fishbane","year":"2019","unstructured":"Fishbane S, Ford M, Fukagawa M et al (2019) A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia. J Am Soc Nephrol 30:1723\u20131733. https:\/\/doi.org\/10.1681\/ASN.2019050450","journal-title":"J Am Soc Nephrol"},{"key":"5298_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA et al (2015) Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372:211\u2013221. https:\/\/doi.org\/10.1056\/NEJMoa1410853","journal-title":"N Engl J Med"},{"key":"5298_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/DHPS.S338579","volume":"14","author":"G Colbert","year":"2022","unstructured":"Colbert G, Sannapaneni S, Lerma EV (2022) Clinical efficacy, safety, tolerability, and real-world data of patiromer for the treatment of hyperkalemia. DHPS 14:87\u201396. https:\/\/doi.org\/10.2147\/DHPS.S338579","journal-title":"DHPS"},{"issue":"1714\/3228","key":"5298_CR20","first-page":"32054","volume":"10","author":"L De Nicola","year":"2019","unstructured":"De Nicola L, Garofalo C, Provenzano M et al (2019) La gestione dell\u2019iperpotassiemia: nefrologo e cardiologo a confronto. Giornale Italiano di Cardiologia DOI 10(1714\/3228):32054","journal-title":"Giornale Italiano di Cardiologia DOI"},{"key":"5298_CR21","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.34067\/KID.0000000586","volume":"5","author":"NR Desai","year":"2024","unstructured":"Desai NR, Kammerer J, Budden J et al (2024) The association of heart failure and edema events between patients initiating sodium zirconium cyclosilicate or patiromer. Kidney 360 5:1835\u20131843. https:\/\/doi.org\/10.34067\/KID.0000000586","journal-title":"Kidney 360"},{"key":"5298_CR22","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.cardfail.2022.04.003","volume":"28","author":"M Zhuo","year":"2022","unstructured":"Zhuo M, Kim SC, Patorno E, Paik JM (2022) Risk of hospitalization for heart failure in patients with hyperkalemia treated with sodium zirconium cyclosilicate versus patiromer. J Card Fail 28:1414\u20131423. https:\/\/doi.org\/10.1016\/j.cardfail.2022.04.003","journal-title":"J Card Fail"},{"key":"5298_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195820","volume":"11","author":"V Perrone","year":"2022","unstructured":"Perrone V, Veronesi C, Dovizio M et al (2022) The influence of iron-deficiency anaemia (IDA) therapy on clinical outcomes and healthcare resource consumptions in chronic kidney disease patients affected by IDA: a real-word evidence study among the Italian population. J Clin Med 11:5820. https:\/\/doi.org\/10.3390\/jcm11195820","journal-title":"J Clin Med"},{"key":"5298_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"5298_CR25","doi-asserted-by":"publisher","first-page":"264.e9","DOI":"10.1016\/j.amjmed.2012.08.016","volume":"126","author":"Z Harel","year":"2013","unstructured":"Harel Z, Harel S, Shah PS et al (2013) Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med 126:264.e9-264.e24. https:\/\/doi.org\/10.1016\/j.amjmed.2012.08.016","journal-title":"Am J Med"},{"key":"5298_CR26","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamainternmed.2019.0631","volume":"179","author":"JA Noel","year":"2019","unstructured":"Noel JA, Bota SE, Petrcich W et al (2019) Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA Intern Med 179:1025. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0631","journal-title":"JAMA Intern Med"},{"key":"5298_CR27","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.kint.2015.11.018","volume":"89","author":"RH Sterns","year":"2016","unstructured":"Sterns RH, Grieff M, Bernstein PL (2016) Treatment of hyperkalemia: something old, something new. Kidney Int 89:546\u2013554. https:\/\/doi.org\/10.1016\/j.kint.2015.11.018","journal-title":"Kidney Int"},{"key":"5298_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.mayocp.2019.05.019","volume":"95","author":"BF Palmer","year":"2020","unstructured":"Palmer BF (2020) Potassium binders for hyperkalemia in chronic kidney disease\u2014diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis. Mayo Clin Proc 95:339\u2013354. https:\/\/doi.org\/10.1016\/j.mayocp.2019.05.019","journal-title":"Mayo Clin Proc"},{"key":"5298_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1681\/ASN.2010010079","volume":"21","author":"RH Sterns","year":"2010","unstructured":"Sterns RH, Rojas M, Bernstein P, Chennupati S (2010) Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 21:733\u2013735. https:\/\/doi.org\/10.1681\/ASN.2010010079","journal-title":"J Am Soc Nephrol"},{"key":"5298_CR30","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod M, Rasmussen HS, Lavin P et al (2014) Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 312:2223. https:\/\/doi.org\/10.1001\/jama.2014.15688","journal-title":"JAMA"},{"key":"5298_CR31","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1002\/ehf2.13976","volume":"9","author":"A Esteban-Fern\u00e1ndez","year":"2022","unstructured":"Esteban-Fern\u00e1ndez A, Ortiz Cort\u00e9s C, L\u00f3pez-Fern\u00e1ndez S et al (2022) Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life. ESC Heart Fail 9:3071\u20133078. https:\/\/doi.org\/10.1002\/ehf2.13976","journal-title":"ESC Heart Fail"},{"key":"5298_CR32","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/ehf2.12292","volume":"5","author":"B Pitt","year":"2018","unstructured":"Pitt B, Bakris GL, Weir MR et al (2018) Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes\/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail 5:592\u2013602. https:\/\/doi.org\/10.1002\/ehf2.12292","journal-title":"ESC Heart Fail"},{"key":"5298_CR33","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10741-020-10069-3","volume":"26","author":"J Silva-Cardoso","year":"2021","unstructured":"Silva-Cardoso J, Brito D, Fraz\u00e3o JM et al (2021) Management of RAASi-associated hyperkalemia in patients with cardiovascular disease. Heart Fail Rev 26:891\u2013896. https:\/\/doi.org\/10.1007\/s10741-020-10069-3","journal-title":"Heart Fail Rev"},{"key":"5298_CR34","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s40265-025-02198-6","volume":"85","author":"N Huang","year":"2025","unstructured":"Huang N, Xu Y, Liu C et al (2025) Novel potassium binders in reduction of hyperkalemia and optimization of RAAS inhibitors treatment in patients with chronic kidney disease or heart failure: a systematic review and meta-analysis. Drugs 85:1013\u20131031. https:\/\/doi.org\/10.1007\/s40265-025-02198-6","journal-title":"Drugs"},{"key":"5298_CR35","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000533753","volume":"54","author":"R Chinnadurai","year":"2023","unstructured":"Chinnadurai R, Rengarajan S, Budden JJ et al (2023) Maintaining renin-angiotensin-aldosterone system inhibitor treatment with patiromer in hyperkalaemic chronic kidney disease patients: comparison of a propensity-matched real-world population with AMETHYST-DN. Am J Nephrol 54:408\u2013415. https:\/\/doi.org\/10.1159\/000533753","journal-title":"Am J Nephrol"},{"key":"5298_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04194-0","volume":"26","author":"JK-C Ng","year":"2025","unstructured":"Ng JK-C, Fung WW-S, Chan GC-K et al (2025) Intermittent sodium zirconium cyclosilicate for the prevention of hyperkalemia in chronic kidney disease. BMC Nephrol 26:260. https:\/\/doi.org\/10.1186\/s12882-025-04194-0","journal-title":"BMC Nephrol"},{"key":"5298_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114197","volume":"158","author":"R Fernandez-Prado","year":"2023","unstructured":"Fernandez-Prado R, Villalvazo P, Avello A et al (2023) Sodium zirconium cyclosilicate and metabolic acidosis: potential mechanisms and clinical consequences. Biomed Pharmacother 158:114197. https:\/\/doi.org\/10.1016\/j.biopha.2022.114197","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"5298_CR38","first-page":"37","volume":"36","author":"L Degli Esposti","year":"2019","unstructured":"Degli Esposti L, Perrone V, Giacomini E et al (2019) Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease. G Ital Nefrol 36(5):37\u201349","journal-title":"G Ital Nefrol"},{"key":"5298_CR39","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s41669-022-00357-z","volume":"6","author":"T Ward","year":"2022","unstructured":"Ward T, Brown T, Lewis RD et al (2022) The cost effectiveness of patiromer for the treatment of hyperkalaemia in patients with chronic kidney disease with and without heart failure in Ireland. Pharmacoecon Open 6:757\u2013771. https:\/\/doi.org\/10.1007\/s41669-022-00357-z","journal-title":"Pharmacoecon Open"},{"key":"5298_CR40","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1080\/13696998.2024.2382033","volume":"27","author":"A Ramirez De Arellano","year":"2024","unstructured":"Ramirez De Arellano A, Jakutis G, Hunt B (2024) Cost analysis of patiromer vs sodium zirconium cyclosilicate for the treatment of hyperkalemia in Spain and the UK. J Med Econ 27:1011\u20131017. https:\/\/doi.org\/10.1080\/13696998.2024.2382033","journal-title":"J Med Econ"},{"key":"5298_CR41","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1159\/000545622","volume":"15","author":"M Wang","year":"2025","unstructured":"Wang M, Zuo L (2025) Cardiorenal benefits of SGLT2 inhibitors in patients with chronic kidney disease and concomitant hypertension. Cardiorenal Med 15:496\u2013509. https:\/\/doi.org\/10.1159\/000545622","journal-title":"Cardiorenal Med"},{"key":"5298_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1429261","volume":"15","author":"S-Q Yang","year":"2024","unstructured":"Yang S-Q, Zhao X, Zhang J et al (2024) Comparative efficacy and safety of SGLT2is and ns-MRAs in patients with diabetic kidney disease: a systematic review and network meta-analysis. Front Endocrinol 15:1429261. https:\/\/doi.org\/10.3389\/fendo.2024.1429261","journal-title":"Front Endocrinol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05298-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05298-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05298-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:25:48Z","timestamp":1785518748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05298-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":42,"alternative-id":["5298"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05298-8","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}